ERR Agonists in Metabolic Research

Last updated: May 2026 · Reviewed for accuracy against current published literature

Table of Contents

1. What Are ERR Agonists?
2. The ERR Family of Nuclear Receptors
3. How ERR Agonists Work — The Mechanism in Detail
4. Why ERR Agonists Matter — Research Applications
5. The Major ERR Agonists — A Comparative Analysis
6. ERR Agonists vs Other Exercise-Mimetic Pathways
7. What to Look for When Buying ERR Agonist Research Compounds
8. Common ERR Research Methods and Biomarkers
9. Limitations and Open Questions in ERR Research
10. The Future of ERR Agonist Research
11. Frequently Asked Questions

What Are ERR Agonists?

ERR agonists are small-molecule compounds that bind and activate the estrogen-related receptors — ERRα, ERRβ and ERRγ — a family of orphan nuclear receptors that control mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the transcriptional program of endurance exercise. In research models, ERR agonists pharmacologically reproduce the metabolic and gene-expression adaptations normally driven by sustained aerobic exercise, which is why the published literature consistently classifies them as “exercise mimetic” chemical tools.

The term “agonist” means the compound activates the receptor when it binds — in contrast to inverse agonists (which suppress receptor activity below baseline) or antagonists (which block agonist binding without changing baseline activity). ERR agonists are therefore positive activators of the ERR transcriptional program, driving downstream gene expression that increases mitochondrial content, oxidative capacity and fatty-acid utilization in target tissues.

Within the broader landscape of metabolic-research compounds — which includes PPARδ agonists, AMPK activators, Rev-Erb agonists and SIRT1 modulators — ERR agonists occupy a distinct mechanistic niche. They directly engage nuclear-receptor transcription factors, working through a cleaner and more selective transcriptional pathway than energy-stress sensors like AMPK or broader pleiotropic targets like SIRT1. This makes them particularly valuable as chemical tools when researchers need to isolate the contribution of the ERR/PGC-1α axis from other metabolic regulators.

The most-studied ERR agonist as of 2026 is SLU-PP-332 (commonly nicknamed “Sloop”), a synthetic small molecule developed at Saint Louis University. SLU-PP-332 is a pan-agonist with strongest activity at ERRα and is the reference compound for current preclinical research on the receptor family. Sourcetides supplies SLU-PP-332 (Sloop) at ≥99% purity for laboratory research.

Why ERR agonists are getting attention in 2026

Three converging factors put ERR agonists at the centre of current metabolic-research interest. First, the 2023 publication of SLU-PP-332 by Billon and colleagues in ACS Chemical Biology gave researchers the first well-characterized pan-ERR agonist with documented in-vivo efficacy in mice. Second, follow-up work in 2024 in the Journal of Pharmacology and Experimental Therapeutics demonstrated that chronic SLU-PP-332 administration reduced fat mass and improved glucose tolerance in obese mouse models — results that placed ERR pan-agonism on the map for metabolic-syndrome research. Third, the broader scientific interest in “exercise in a pill” concepts — pharmacologically reproducing the benefits of aerobic exercise in research models where exercise is not feasible — has driven new investment in studying small-molecule activators of the exercise transcriptional program.

The result is that ERR agonists have moved from a relatively obscure corner of nuclear-receptor pharmacology into a focal area of preclinical metabolic research, with associated demand for high-quality research-grade material from suppliers who understand the compound class. Sourcetides classifies and supplies ERR agonists by their correct chemical identity — as small-molecule nuclear-receptor ligands — rather than mislabeling them as peptides as many retail platforms do. [[INTERNAL LINK: Why SLU-PP-332 is not a peptide — clarifying the classification]]

The ERR Family of Nuclear Receptors

To understand ERR agonists you need to understand the receptors they target. The estrogen-related receptors are a small family of three closely related nuclear-receptor transcription factors: ERRα, ERRβ and ERRγ. They were originally identified in the late 1980s based on sequence homology with the classical estrogen receptors (ERα and ERβ), which gave rise to the “estrogen-related” name. The name is misleading. ERRs do not bind estrogen at any physiologically relevant concentration, and they regulate gene programs that are largely independent of estrogen-receptor signaling.

For decades after their discovery, ERRs were classified as “orphan nuclear receptors” because no endogenous ligand had been identified for them. They remained largely uncharacterized until the early 2000s, when work by several research groups established their roles in mitochondrial biology and metabolism. ERRs are now understood to function as metabolic master regulators, sitting at the apex of the transcriptional control of mitochondrial biogenesis, oxidative phosphorylation, the tricarboxylic acid (TCA) cycle and fatty-acid β-oxidation in tissues with high energy demand.

ERRα (NR3B1)

ERRα is the most extensively studied ERR isoform and the primary target of most current ERR-agonist research. It is highly expressed in skeletal muscle, brown adipose tissue, liver and kidney — tissues defined by high mitochondrial content and oxidative capacity. ERRα serves as the central transcriptional partner of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master coactivator of mitochondrial biogenesis. The ERRα/PGC-1α axis controls the expression of an extensive network of nuclear-encoded mitochondrial proteins, including OXPHOS complex subunits, fatty-acid oxidation enzymes (CPT1b, MCAD, LCAD), TCA cycle enzymes and mitochondrial transcription factors (TFAM, NRF1, NRF2). When researchers refer to “the ERR pathway” in the context of exercise mimetics or mitochondrial biogenesis, they almost always mean the ERRα arm of this signaling network.

Pharmacologically, ERRα is the highest-priority target for current pan-agonists like SLU-PP-332, which shows EC₅₀ values around 98 nM at ERRα in cell-based reporter assays — roughly 4–5 times more potent than at ERRγ. [[INTERNAL LINK: ERR alpha biology and research applications — cluster post]]

ERRβ (NR3B2)

ERRβ has a more restricted expression profile than ERRα. It is highly expressed in embryonic stem cells, the retina, and a limited subset of adult metabolic tissues. ERRβ is functionally important in early embryonic development — ERRβ knockout in mice is embryonic-lethal due to placental defects — but its role in adult metabolic physiology is less well-characterized than ERRα. In current ERR-agonist research, ERRβ is generally considered a secondary target rather than a primary one. Compounds like GSK4716 are selective for ERRβ and ERRγ over ERRα, and these are the appropriate tools for ERRβ-selective experimental questions. [[INTERNAL LINK: GSK4716 vs SLU-PP-332 — choosing the right ERR tool compound]]

ERRγ (NR3B3)

ERRγ is highly expressed in cardiac muscle, oxidative slow-twitch (type IIa) skeletal-muscle fibers, brown adipose tissue and certain neuronal populations. In the heart, ERRγ plays a particularly important role in the perinatal switch from glycolytic to oxidative metabolism, and ERRγ signaling is critical for normal cardiac mitochondrial function throughout life. ERRγ-selective research is therefore relevant to cardiovascular research applications, while pan-ERR agonism (which engages ERRγ alongside ERRα and ERRβ) provides a tool for studies that need broad ERR-family activation. The published characterization of SLU-PP-332 includes activity at ERRγ with an EC₅₀ around 430 nM, lower potency than at ERRα but still pharmacologically meaningful at typical research concentrations.

Why the ERR family matters as a coordinated unit

ERRα, ERRβ and ERRγ share substantial structural and functional homology and bind overlapping (though not identical) sets of ERR-response-element (ERRE) DNA motifs. In tissues where multiple isoforms are co-expressed, they cooperate to drive metabolic gene expression. Endurance exercise activates all three isoforms physiologically through upstream signaling cascades, and the collective ERR-family transcriptional response is what produces the full exercise adaptation phenotype. This is why pan-ERR agonists like SLU-PP-332 are particularly attractive as exercise-mimetic research tools — they engage the entire receptor family in a manner analogous to the physiological exercise response, rather than producing the partial receptor activation typical of selective ligands. Background reference: ERRα on Wikipedia.

How ERR Agonists Work — The Mechanism in Detail

The mechanism of ERR agonists involves four sequential events: ligand binding to the receptor’s ligand-binding domain (LBD), recruitment of the PGC-1α coactivator, assembly of the active transcriptional complex on ERRE DNA motifs, and downstream gene transcription that produces the metabolic-adaptation phenotype. Each step is worth understanding because it determines what the compound does at the molecular level and what experimental readouts will reflect activity.

Step 1: Ligand binding to the LBD

Like other nuclear receptors, ERRs have a modular structure: an N-terminal activation domain, a central DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD) that contains the agonist-binding pocket. ERR agonists like SLU-PP-332 enter the LBD pocket and form specific interactions with conserved amino-acid residues in the binding cavity. In the case of SLU-PP-332, the naphthyl group on the molecule forms π-π stacking interactions with phenylalanine residues in the ERRα LBD — a structural feature inherited from the parent scaffold compound GSK4716, modified to gain ERRα activity that GSK4716 itself largely lacks. The binding of an agonist stabilizes the receptor’s LBD in an “agonist conformation” that exposes a coactivator-binding surface on the receptor exterior — this exposed surface is the platform on which the next step occurs.

Step 2: PGC-1α coactivator recruitment

The agonist conformation of ERRs creates a hydrophobic groove on the receptor surface that recruits transcriptional coactivators — proteins that physically link the receptor to the basal transcription machinery. The dominant coactivator partner of activated ERRs is PGC-1α, the master regulator of mitochondrial biogenesis. PGC-1α binds to activated ERRs through an LXXLL motif (a five-amino-acid sequence common to nuclear-receptor coactivators) and assembles a larger transcriptional complex that includes mediator proteins, RNA polymerase II, and chromatin-remodeling enzymes. The ERR/PGC-1α complex is the functional unit that drives downstream gene expression — without PGC-1α, ERR activation produces a substantially diminished transcriptional response.

This is mechanistically important because PGC-1α itself is a major target of upstream regulation by AMPK, calcium/calmodulin signaling and nutrient-sensing pathways. The ERR/PGC-1α axis therefore integrates pharmacological ERR activation with the broader cellular energy state, which is part of why ERR agonists produce coherent metabolic adaptations rather than dysregulated transcriptional noise. [[INTERNAL LINK: PGC-1 alpha — the master regulator of mitochondrial biogenesis — cluster post]]

Step 3: Assembly on ERRE DNA motifs

The ERR/PGC-1α complex binds DNA at ERR-response elements (ERREs) — short DNA sequences with the consensus motif TCAAGGTCA. ERREs are distributed across the genome upstream of and within the regulatory regions of mitochondrial and metabolic genes. ChIP-seq and RNA-seq studies have mapped thousands of ERR-binding sites across the genome of metabolically active tissues like skeletal muscle. Once bound, the complex recruits transcriptional machinery and initiates messenger RNA synthesis from the target gene.

Step 4: Downstream gene transcription — what gets activated

The transcriptional response to ERR-agonist treatment in research models has been characterized in detail and includes upregulation of:

• Mitochondrial biogenesis transcription factors: NRF1, NRF2 (nuclear respiratory factors), TFAM (mitochondrial transcription factor A — the regulator of mitochondrial DNA replication and transcription)
• OXPHOS complex subunits: components of all five complexes of the electron transport chain, including cytochrome c, ATP synthase subunits, NADH dehydrogenase subunits
• Fatty-acid β-oxidation enzymes: CPT1b (the rate-limiting enzyme for mitochondrial fatty-acid uptake in muscle), MCAD, LCAD, ACADVL (acyl-CoA dehydrogenases)
• TCA cycle enzymes: citrate synthase (frequently used as a proxy for mitochondrial density), isocitrate dehydrogenase, succinate dehydrogenase complex subunits
• Acute exercise-response genes: notably DDIT4 (also called REDD1), an ERRα-dependent early-response transcript that is one of the most reliable rapid biomarkers of acute aerobic exercise in skeletal muscle
• Type IIa fiber markers: myosin heavy chain isoforms associated with oxidative slow-twitch muscle fibers

The phenotypic outcome of this transcriptional response in research models includes increased mitochondrial density in target tissues, elevated oxidative capacity, a shift in muscle-fiber composition toward oxidative type IIa fibers, and increased treadmill-running endurance in mice. See Billon et al. 2023 on PubMed for the foundational characterization. [[INTERNAL LINK: How does SLU-PP-332 work? The ERR mechanism explained — cluster post]]

Why ERR Agonists Matter — Research Applications

ERR agonists are used across several active preclinical research programs, each defined by a different experimental question. Understanding the breadth of applications is part of why the compound class has expanded so quickly in current research.

Mitochondrial biogenesis studies

The most direct application of ERR agonists is in research on mitochondrial biogenesis — the cellular process of producing new mitochondria. ERR agonists serve as positive-control tools or as primary research interventions to drive biogenesis pharmacologically, allowing researchers to dissect the transcriptional control of the process and to test downstream readouts. Standard endpoints in this work include mitochondrial DNA copy number (qPCR), citrate synthase activity, OXPHOS protein expression by Western blot, mitochondrial membrane potential by JC-1 staining, and mitochondrial respiration by Seahorse XF respirometry (basal OCR, maximal OCR after FCCP uncoupling, spare respiratory capacity). [[INTERNAL LINK: Seahorse XF respirometry with SLU-PP-332-treated cells — methods cluster post]]

Exercise mimetic and endurance research

ERR agonists are the cleanest available pharmacological tool for studying the transcriptional component of exercise adaptation. Researchers compare ERR-agonist-treated sedentary animals against exercised animals to isolate which adaptations require physical activity per se versus which can be driven purely by ERR transcriptional engagement. This experimental design has produced informative data on the boundaries of the “exercise gene program” and the proportion of exercise adaptation that is mechanistically attributable to ERR activation. Endpoints include treadmill time-to-exhaustion, oxidative fiber-type quantification by immunohistochemistry, and gene-expression panels for exercise-response transcripts (DDIT4, TFAM, CPT1b, NRF1). [[INTERNAL LINK: Using SLU-PP-332 in mouse treadmill endurance studies — methods cluster post]]

Metabolic syndrome and obesity models

Following the 2024 Banerjee et al. data showing that SLU-PP-332 reduced fat mass and improved glucose tolerance in DIO and ob/ob mice, ERR agonists have entered active research use in metabolic-syndrome models. Standard endpoints include body composition by EchoMRI or DEXA, glucose tolerance tests (GTT), insulin tolerance tests (ITT), homeostatic model assessment of insulin resistance (HOMA-IR), and indirect calorimetry for whole-body energy expenditure and respiratory exchange ratio. Full text of the Banerjee 2024 paper on PMC.

Cardiac and renal research

ERRγ expression in cardiac muscle and the published 2023 Wang et al. data on ERR-agonist reversal of mitochondrial dysfunction in aged-kidney models have established ERR agonists as research tools beyond skeletal muscle. Cardiac applications focus on the role of ERRγ in maintaining oxidative cardiac metabolism; renal applications examine ERR-driven mitochondrial restoration in models of age-related decline. These are smaller research areas than skeletal-muscle metabolism but are growing.

Aging and senescence research

Mitochondrial dysfunction is a hallmark of cellular aging. ERR agonists are being explored as research tools to test the reversibility of age-related mitochondrial decline through pharmacological re-activation of the biogenesis program. This work is at an earlier stage than the metabolic-syndrome research, but it represents a meaningful application area for the compound class. [[INTERNAL LINK: ERR agonists in aging research — cluster post]]

Nuclear-receptor pharmacology and structure-activity relationships

As one of very few pan-ERR agonists with documented in-vivo characterization, SLU-PP-332 also serves as a chemical anchor for medicinal-chemistry programs. Recent structure-activity work (Okda et al. 2026) has produced analogues of the SLU-PP-332 scaffold designed to dissect ERRα/γ selectivity and improve metabolic stability, expanding the toolset available for ERR isoform-specific research. Recent SAR work on the SLU-PP-332 series.

The Major ERR Agonists — A Comparative Analysis

The ERR-agonist landscape in 2026 contains a small number of well-characterized compounds, each with a distinct receptor-selectivity profile. The right tool depends on the experimental question.

SLU-PP-332 (Sloop) — the reference pan-agonist

SLU-PP-332 is currently the most-used ERR agonist in research. It is a pan-agonist with strongest activity at ERRα (EC₅₀ ~98 nM), intermediate activity at ERRβ (~230 nM) and lowest activity at ERRγ (~430 nM). It was developed at Saint Louis University by the Burris laboratory and first published in 2023. The compound has documented in-vivo activity in mice, with reported plasma exposure of approximately 0.2 µM and skeletal muscle exposure of approximately 0.6 µM at 6 hours after intraperitoneal dosing — favorable tissue distribution to the primary target tissue. SLU-PP-332 is a synthetic small molecule (not a peptide) built on the GSK4716 scaffold with a naphthyl substitution that confers ERRα activity.

SLU-PP-332 is the appropriate ERR-agonist tool for: pan-ERR research questions, exercise-mimetic studies, mitochondrial-biogenesis research where ERRα engagement is the priority, metabolic-syndrome models, and chronic-dosing studies that require sustained receptor occupancy. It is supplied as research-grade compressed tablets with a batch-specific Certificate of Analysis. Buy SLU-PP-332 (Sloop) online USA from Sourcetides at ≥99% verified purity. [[INTERNAL LINK: SLU-PP-332 vs Cardarine — mechanism, applications, and research differences — sub-pillar S1]]

GSK4716 — the parent scaffold, ERRβ/γ selective

GSK4716 is an earlier ERR ligand identified in the mid-2000s. It is selective for ERRβ and ERRγ over ERRα — effectively the inverse of the SLU-PP-332 selectivity profile. GSK4716 was the chemical starting point for the medicinal-chemistry work that produced SLU-PP-332, and the two compounds share core structural features. GSK4716 is the appropriate research tool for studies that specifically require ERRβ and/or ERRγ activation without engaging ERRα — cardiac research, retinal biology, ERRγ-driven gene programs. It is less commonly stocked than SLU-PP-332 by research-chemical suppliers but is available for specialized work. [[INTERNAL LINK: GSK4716 vs SLU-PP-332 — choosing the right ERR tool compound — sub-pillar S3]]

DY40 and DY131 — second-generation ERR ligands

DY40 and DY131 are ERRβ/γ agonists from a separate medicinal-chemistry series. They are less widely available than SLU-PP-332 and GSK4716 and primarily appear in academic research from specific laboratories rather than as broadly stocked research-supplier products. They are mentioned here for completeness; for most current ERR-agonist research applications, SLU-PP-332 (pan-agonist) or GSK4716 (ERRβ/γ-selective) covers the experimental needs.

XCT790 — an ERRα inverse agonist (not an agonist)

XCT790 is included here for context because it appears in the ERR research literature, but it is not an ERR agonist. It is an ERRα inverse agonist — a compound that binds the receptor and suppresses its baseline transcriptional activity. XCT790 is used as a chemical knockdown tool to inhibit ERRα function in research models, the opposite experimental objective from SLU-PP-332. Researchers occasionally confuse the two by name; they are mechanistically opposite tools. [[INTERNAL LINK: ERR alpha agonists vs inverse agonists — choosing the right tool — cluster post]]

Comparative summary table

Compound	Selectivity profile	Functional class	Best research use
SLU-PP-332	Pan-ERR (α preference)	Agonist	Pan-ERR research, exercise mimetic studies, mitochondrial biogenesis, metabolic syndrome models
GSK4716	ERRβ/γ selective	Agonist	ERRβ/γ isoform-specific research, cardiac and retinal applications
DY40 / DY131	ERRβ/γ agonists	Agonist	Specialized academic research; less commonly stocked
XCT790	ERRα selective	Inverse agonist (suppresses)	Chemical knockdown of ERRα function (opposite of agonists above)

For most current ERR-agonist research, SLU-PP-332 is the default starting point because it engages all three isoforms in proportions that approximate the physiological exercise response, has documented in-vivo activity in multiple disease models, and has a relatively short but well-characterized publication track record. Research-grade SLU-PP-332 from Sourcetides is the supply path for laboratories requiring verified-purity material with batch-matched documentation.

ERR Agonists vs Other Exercise-Mimetic Pathways

The exercise-mimetic compound class includes several pharmacologically distinct mechanisms beyond the ERR family. Understanding the differences matters for experimental design — the wrong tool for your research question will produce uninterpretable results.

ERR vs PPARδ (Cardarine / GW501516)

PPARδ agonists like GW501516 (commonly called Cardarine in the research-compound market) drive fatty-acid oxidation through a different nuclear-receptor family. PPARδ activation upregulates a partially overlapping but mechanistically distinct gene program from ERR, focused more narrowly on lipid metabolism and less on mitochondrial biogenesis per se. Both compound classes produce endurance enhancement in mouse models, but the upstream signaling and the breadth of the transcriptional response differ. Researchers studying mitochondrial biogenesis specifically should use ERR agonists; researchers studying fatty-acid oxidation can use either, with the choice depending on which receptor pathway is the experimental object. [[INTERNAL LINK: SLU-PP-332 vs Cardarine — sub-pillar S1]]

ERR vs AMPK (AICAR / metformin)

AMPK activators work upstream of ERRs — AMPK phosphorylates and activates PGC-1α, which then partners with ERRs to drive mitochondrial gene expression. AMPK activation is therefore a broader intervention that engages ERR signaling alongside many other AMPK-dependent pathways (autophagy, glucose uptake, lipogenesis suppression). AICAR, the canonical AMPK activator, has a very short plasma half-life and complex pharmacokinetics that complicate in-vivo research. ERR agonists provide a cleaner, more selective entry point into the same downstream gene program without engaging the broader AMPK pleiotropy. [[INTERNAL LINK: SLU-PP-332 vs AICAR — ERR agonism vs AMPK activation — sub-pillar S4]]

ERR vs Rev-Erb (SR9009)

Rev-Erb agonists like SR9009 work through a circadian-clock-linked transcriptional repressor pathway, which is mechanistically distinct from ERR/PGC-1α signaling. Rev-Erb engagement produces metabolic effects with a strong circadian component, and SR9009 in particular has very poor pharmacokinetics that limit its usefulness for in-vivo research. ERR agonists do not have a strong circadian dependence and produce more stable in-vivo activity. [[INTERNAL LINK: SLU-PP-332 vs SR9009 — sub-pillar S2]]

ERR vs SIRT1 (resveratrol pathway)

SIRT1 modulators activate a separate sirtuin deacetylase pathway that intersects with mitochondrial biology indirectly. The literature on direct SIRT1 activators is mixed and the pharmacology is contested. ERR agonists provide a much cleaner direct activator of mitochondrial gene expression than the SIRT1 pathway offers.

Summary table of mechanisms

Pathway	Reference compound	Primary effect	Best fit research question
ERR/PGC-1α	SLU-PP-332	Mitochondrial biogenesis, OXPHOS, fatty-acid oxidation	Mitochondrial biology, exercise gene program, ERR receptor research
PPARδ	GW501516 (Cardarine)	Fatty-acid oxidation	Lipid metabolism, endurance models
AMPK	AICAR	Energy-stress sensing, broad pleiotropy	Energy-state research; not isoform-selective
Rev-Erb	SR9009	Circadian-metabolic crosstalk	Chronobiology research; PK-limited
SIRT1	Resveratrol (indirect)	Sirtuin deacetylation activity	Sirtuin pathway research; pharmacology contested

The takeaway: ERR agonists are not interchangeable with PPARδ, AMPK, Rev-Erb or SIRT1 modulators. They occupy a specific and important position in the metabolic-research pharmacology toolkit, and for research questions involving mitochondrial biogenesis or the exercise transcriptional program, they are the cleanest available tool.

What to Look for When Buying ERR Agonist Research Compounds

The research-chemical market contains suppliers across a wide quality spectrum. For ERR agonists specifically — and SLU-PP-332 in particular — the differences between high-quality and low-quality supply are large and often invisible until the compound underperforms in the lab. Here is what serious laboratories should require from any ERR-agonist supplier.

Verified purity, not estimated purity

Research-grade ERR agonists should be supplied at ≥99% purity, demonstrated by reverse-phase HPLC analysis with a visible chromatographic trace and integrated peak percentage. Suppliers who report purity without producing the underlying analytical data are asking buyers to take quality on trust. Always require the analytical document, not just a certificate number. [[INTERNAL LINK: SLU-PP-332 purity standards — how to verify what you are buying — sub-pillar S6]]

Identity confirmation by mass spectrometry

HPLC purity confirms that the dominant peak in the sample is a single compound — it does not confirm which compound. Mass-spectrometry analysis is the standard for confirming compound identity against the reference molecular weight of the target. Any ERR-agonist supplier worth ordering from will provide MS confirmation alongside HPLC purity. Suppliers that do not provide MS data should be approached with caution; the compound in your bottle could pass HPLC purity testing while being chemically wrong.

Batch-specific COA

Generic Certificate of Analysis documents that are reused across multiple production lots are not informative. The COA you receive should reference the exact lot number on your physical bottle, the date the batch was analyzed, the analytical lab name, and the methods used. Researchers running multi-batch studies need batch-matched COAs to maintain reproducibility documentation across production runs. [[INTERNAL LINK: How to read a SLU-PP-332 Certificate of Analysis — cluster post]]

Independent third-party testing

Suppliers who test their own compounds on in-house instruments are subject to obvious conflict-of-interest concerns. Independent third-party laboratory analysis — performed by a lab unaffiliated with the supplier — is the standard for credible research-chemical supply. The COA should identify the testing laboratory by name.

Supply transparency and traceability

Research-grade suppliers are transparent about their manufacturing chain. They identify the synthesis source, the analytical lab, the production lot, and the batch date. Suppliers who obscure these details — selling “bulk” material of untraceable origin or refusing to confirm where compounds were synthesized — are not appropriate for institutional research. Sourcetides supplies ERR agonist research compounds with full lot traceability and batch-matched analytical documentation.

US-based dispatch vs international supply

For researchers in the United States, US-based dispatch is the practical choice. International shipments of research chemicals carry customs risk, longer transit times, and the possibility of seizure on arrival — a research-program disruption that has nothing to do with the supplier’s compound quality. Same-day US dispatch from a domestic facility eliminates this category of risk entirely. SLU-PP-332 from Sourcetides ships same-day from the United States on orders placed before 12:00 PM EST. [[INTERNAL LINK: Where to buy SLU-PP-332 online — quality-first buyer’s guide — sub-pillar S5]]

Correct chemical classification

SLU-PP-332 and other ERR agonists are not peptides — they are synthetic small molecules. Suppliers who classify them as “peptides” in their listings are technically incorrect and frequently provide handling and storage guidance derived from peptide protocols rather than small-molecule chemistry. Correct classification is a basic competency signal: a supplier who does not know what they are selling cannot be trusted to handle it correctly during storage and shipment. [[INTERNAL LINK: Why SLU-PP-332 is not a peptide — cluster post]]

Common ERR Research Methods and Biomarkers

Researchers using ERR agonists need reliable readouts that confirm compound activity in their experimental system. The methods below are the standard panel used to validate ERR pathway engagement in cell-culture and in-vivo research.

Reporter assays for direct receptor engagement

Cell-based luciferase reporter assays using ERRE-driven reporters are the gold-standard method for confirming direct receptor activation by an agonist. Cells are co-transfected with an expression vector for ERRα, ERRβ or ERRγ and a reporter plasmid containing ERRE response elements driving luciferase expression. Treatment with the agonist produces a dose-dependent increase in reporter signal, and EC₅₀ values are extracted from the dose-response curve. This is the assay format used by Billon et al. to characterize SLU-PP-332. [[INTERNAL LINK: Reporter assays for nuclear receptor research — cluster post]]

qPCR biomarker panels

Quantitative real-time PCR for ERR-pathway target genes is the most widely used in-vitro and in-vivo readout of ERR-agonist activity. The standard panel includes:

• DDIT4 (REDD1) — one of the most rapidly and robustly induced ERRα-dependent transcripts; sensitive marker of acute pathway engagement
• TFAM — mitochondrial transcription factor A; mid-range biogenesis marker
• NRF1 — nuclear respiratory factor 1; downstream of PGC-1α
• CPT1b — carnitine palmitoyltransferase 1b; rate-limiting step of muscle fatty-acid oxidation
• PPARGC1A (PGC-1α itself) — useful as a feedback-loop marker
• MCAD, LCAD, ACADVL — acyl-CoA dehydrogenase enzymes for fatty-acid β-oxidation

A 6-gene qPCR panel covering DDIT4, TFAM, NRF1, CPT1b, PPARGC1A and a housekeeper (GAPDH or 18S rRNA) provides a robust readout of ERR-agonist activity at both early time points (DDIT4 induction within hours) and longer time points (TFAM, CPT1b induction within 24–48 hours).

Western blot for protein-level confirmation

Protein-level confirmation of mRNA changes is standard for rigorous ERR research. Targets include OXPHOS complex subunits (using the OXPHOS rodent or human antibody cocktail commonly available commercially), TFAM, NRF1, CPT1b protein, and cytochrome c. Quantification by densitometry against a loading control (GAPDH, β-actin or total-protein normalization).

Seahorse XF respirometry

Functional confirmation that the ERR agonist has driven a metabolically meaningful change is best provided by Seahorse XF cellular respirometry. Key endpoints: basal oxygen consumption rate (basal OCR), maximal OCR after FCCP-induced uncoupling, spare respiratory capacity (the difference between maximal and basal), and the basal extracellular acidification rate (ECAR) as an inverse marker of glycolytic dependence. ERR agonists driving mitochondrial biogenesis should produce elevated maximal OCR and increased spare respiratory capacity over time, consistent with greater mitochondrial content. [[INTERNAL LINK: Seahorse XF respirometry methods for ERR research — cluster post]]

Citrate synthase activity assay

Citrate synthase activity is a widely used proxy for mitochondrial density. The assay is simple, reproducible, and provides a quantitative readout of biogenesis-driven changes in mitochondrial content per cell or per unit of tissue.

In-vivo phenotypic readouts

For in-vivo work, the standard endpoints depend on the research question. Skeletal-muscle endurance research uses treadmill time-to-exhaustion. Metabolic-syndrome research uses body composition (EchoMRI), glucose tolerance testing, insulin tolerance testing, and indirect calorimetry. Cardiac and renal research use tissue-specific functional and histological endpoints. ERR-agonist activity should produce coherent changes across multiple readouts — an agonist that increases TFAM mRNA but does not affect any functional mitochondrial readout is unlikely to be active enough to interpret. [[INTERNAL LINK: qPCR biomarker panel for SLU-PP-332 activity validation — cluster post]]

Limitations and Open Questions in ERR Research

Honest research-supplier content acknowledges the boundaries of what ERR agonists currently can and cannot do. Several limitations are relevant for laboratories planning new work in this area.

No human pharmacokinetic data

All published efficacy and safety data on ERR agonists are from cell-based assays and rodent studies. There are no completed human clinical trials of SLU-PP-332 or any other ERR agonist as of 2026, and no human pharmacokinetic characterization. Researchers should not extrapolate rodent dosing to human-equivalent doses for any purpose; this is both bad pharmacology and outside the regulatory scope of research-use-only supply.

Short rodent half-life requires frequent dosing

SLU-PP-332 has a relatively short plasma half-life in rodents, which is why published chronic-dosing protocols use twice-daily administration. This is manageable in research studies but represents a real practical constraint for protocols requiring sustained receptor occupancy. Future medicinal-chemistry work on ERR-agonist pharmacokinetic improvement is an active area of academic research.

Long-term safety in animals not fully characterized

The published chronic-dosing data on SLU-PP-332 covers weeks-to-months timeframes in mice. Longer-term studies are still in progress. ERRα signaling has been linked in some research contexts to roles outside metabolism (including in cancer biology), and the long-term consequences of sustained pharmacological pan-ERR activation in animal models remain an area of active investigation. Researchers designing chronic studies should follow current published protocols and stay aware of emerging safety data.

Receptor-specific selectivity remains a challenge

Current ERR agonists are either pan-agonists (SLU-PP-332) or ERRβ/γ-selective (GSK4716, DY40). A truly ERRα-selective agonist suitable for in-vivo research is still in development. For research questions that require ERRα-specific activation without ERRβ or ERRγ engagement, the available pharmacological tools remain limited; genetic approaches (tissue-specific knockouts, conditional alleles) are often more appropriate for isoform-selective questions.

Off-target effects under investigation

Like all small-molecule research compounds, ERR agonists may have off-target binding partners that have not been fully characterized. The available evidence indicates that SLU-PP-332 is reasonably selective for the ERR family within the nuclear-receptor superfamily, but comprehensive off-target profiling is still ongoing. Researchers should include appropriate controls (vehicle, ERR knockout/knockdown comparison where feasible) to attribute experimental effects specifically to ERR activation rather than off-target activity.

The Future of ERR Agonist Research

The ERR-agonist field is in active expansion. Several near-term developments are likely to shape the next phase of research.

Improved isoform selectivity. The Okda et al. 2026 work and similar medicinal-chemistry programs are producing analogues of the SLU-PP-332 scaffold with shifted ERRα/γ selectivity ratios. A genuinely ERRα-selective agonist suitable for in-vivo research would substantially expand the toolkit. Watch the medicinal-chemistry literature in 2026–2027 for new compound disclosures.

Improved pharmacokinetics. The short half-life of SLU-PP-332 in rodents is a practical limitation for chronic-dosing studies. Next-generation analogues with extended half-life would simplify experimental design.

Broader disease-model coverage. Beyond skeletal-muscle metabolism and obesity, current research is extending into cardiac, renal, hepatic and neurological models. The breadth of ERR expression across tissues means the receptor family is relevant to many areas of metabolic-research interest.

Expanded availability. As demand for ERR-agonist research compounds grows, the supplier landscape is expanding — with associated quality variability. Research labs prioritizing reproducibility will continue to favor suppliers with batch-matched analytical documentation, third-party testing and US-based dispatch over commodity sources. [[INTERNAL LINK: 2026 metabolic research compound trends — cluster post]]

Frequently Asked Questions

What is an ERR agonist?

An ERR agonist is a small-molecule research compound that binds and activates the estrogen-related receptor family (ERRα, ERRβ, ERRγ) — orphan nuclear receptors that control mitochondrial biogenesis, oxidative metabolism and the gene program activated by aerobic exercise. The most-studied ERR agonist in current research is SLU-PP-332, a pan-agonist with strongest activity at ERRα.

Are ERR agonists peptides?

No. ERR agonists are synthetic small molecules — not peptides. Despite frequent mislabeling on retail platforms, compounds like SLU-PP-332 contain no amino acids, no peptide bonds and no peptide sequence. They are non-peptidic organic compounds that bind nuclear-receptor ligand-binding domains.

What is the difference between ERR agonists and estrogen receptor agonists?

ERRs (estrogen-related receptors) and classical ERs (estrogen receptors) share sequence homology but bind different ligands and regulate different gene programs. ERRs do not bind estrogen, and ERR agonists do not engage classical estrogen receptors at relevant concentrations. The two receptor families are functionally separate.

Which is the best ERR agonist for research use?

For most current ERR-agonist research, SLU-PP-332 is the default choice because it is a pan-agonist engaging all three ERR isoforms with documented in-vivo activity in mouse models. For ERRβ/γ-selective research questions, GSK4716 is the appropriate alternative. The right choice depends on the experimental question.

Can ERR agonists replace exercise in research models?

ERR agonists pharmacologically reproduce a substantial portion of the transcriptional response to aerobic exercise in research models, but they do not reproduce the full physiological exercise adaptation. Mechanical loading, cardiovascular adaptations and other exercise-driven processes are not engaged by ERR-agonist treatment. They are research tools to dissect the transcriptional component of exercise adaptation, not exercise replacements.

Are ERR agonists safe?

ERR agonists are research-use-only compounds that have not been evaluated for human safety. All available data are from cell-based assays and rodent studies. They should be used only by qualified researchers in compliant laboratory settings, in accordance with research-use-only supply terms.

How are ERR agonists dosed in research models?

Published in-vivo dosing protocols for SLU-PP-332 in mice typically use 30–50 mg/kg by intraperitoneal administration, with twice-daily dosing in chronic studies due to the relatively short rodent half-life. Researchers should follow current published protocols specific to their experimental model.

Where can researchers buy ERR agonists in the USA?

Research-grade ERR agonists, including SLU-PP-332, are supplied by specialized research-chemical companies. Sourcetides supplies SLU-PP-332 (Sloop) at ≥99% verified purity with batch-specific Certificate of Analysis and same-day US dispatch. Buy SLU-PP-332 online from Sourcetides USA.

What is the difference between ERR agonists and PPAR agonists?

ERR agonists target the estrogen-related receptor family and drive mitochondrial biogenesis and oxidative metabolism through PGC-1α co-activation. PPAR agonists target the peroxisome proliferator-activated receptors (α, δ, γ), with PPARδ being the closest functional analog — it drives fatty-acid oxidation through a partially overlapping but mechanistically distinct gene program. Researchers studying mitochondrial biogenesis specifically should use ERR agonists.

What biomarkers confirm ERR-agonist activity in cell culture?

The standard biomarker panel for ERR-agonist activity includes DDIT4 (REDD1), TFAM, NRF1, CPT1b and PGC-1α mRNA by qPCR, supplemented with OXPHOS complex protein expression by Western blot and Seahorse XF respirometry for functional confirmation of increased oxidative capacity.

Has SLU-PP-332 been tested in humans?

No. There are no completed human clinical trials of SLU-PP-332 and no FDA-approved indication. SLU-PP-332 is supplied strictly for in-vitro and preclinical research. Any extrapolation from rodent data to human physiology is the responsibility of the investigator and falls outside the scope of research-use-only supply.

How should ERR agonist research compounds be stored?

Solid-form ERR agonists like SLU-PP-332 should be stored sealed at below 25°C in cool, dry, dark conditions. After opening, refrigerate at 2–8°C and reseal between uses. Do not freeze tablets. Stable for 12–24 months under recommended conditions; refer to the batch-specific COA for the lot-specific expiry date.

Final Thoughts: The State of ERR Agonist Research in 2026

ERR agonists have moved from a relatively obscure corner of nuclear-receptor pharmacology into one of the more active areas of metabolic-research interest. The publication of SLU-PP-332 in 2023, the follow-up obesity-model work in 2024, and the rapid expansion of research applications across mitochondrial biogenesis, exercise-mimetic studies, metabolic syndrome and aging research have established the compound class as a core tool for laboratories working on metabolic transcription. The field is still relatively young — comprehensive long-term safety data, fully selective ERRα agonists and improved pharmacokinetics remain on the development horizon — but the available compounds, used appropriately within research-use-only frameworks, now support a wide range of credible experimental work.

For laboratories planning new ERR-agonist research, the practical priorities are: select the right tool for the experimental question (pan-agonist vs. isoform-selective), source from a supplier with verified-purity material and batch-matched documentation, validate compound activity using a standard biomarker panel before drawing experimental conclusions, and design appropriate controls including vehicle and (where feasible) genetic ERR knockouts or knockdowns to attribute observed effects to ERR engagement specifically.

When you build out the cluster posts referenced below, return to this pillar and replace each [[INTERNAL LINK: topic]] placeholder with the actual published URL. Suggested anchor text is included in each placeholder.

1. Why SLU-PP-332 is not a peptide — cluster post (referenced 2× in this pillar)
2. ERR alpha biology and research applications — cluster post
3. GSK4716 vs SLU-PP-332 — choosing the right ERR tool compound — sub-pillar S3 (referenced 2×)
4. PGC-1 alpha — the master regulator of mitochondrial biogenesis — cluster post
5. How does SLU-PP-332 work? The ERR mechanism explained — cluster post
6. Seahorse XF respirometry with SLU-PP-332-treated cells — methods cluster post (referenced 2×)
7. Using SLU-PP-332 in mouse treadmill endurance studies — methods cluster post
8. ERR agonists in aging research — cluster post
9. SLU-PP-332 vs Cardarine — sub-pillar S1 (referenced 2×)
10. SLU-PP-332 vs SR9009 — sub-pillar S2
11. SLU-PP-332 vs AICAR — ERR agonism vs AMPK activation — sub-pillar S4
12. SLU-PP-332 purity standards — how to verify what you are buying — sub-pillar S6
13. How to read a SLU-PP-332 Certificate of Analysis — cluster post
14. Where to buy SLU-PP-332 online — quality-first buyer’s guide — sub-pillar S5
15. Reporter assays for nuclear receptor research — cluster post
16. Seahorse XF respirometry methods for ERR research — cluster post
17. qPCR biomarker panel for SLU-PP-332 activity validation — cluster post
18. 2026 metabolic research compound trends — cluster post
19. ERR alpha agonists vs inverse agonists — choosing the right tool — cluster post

Total internal-link slots in this pillar: 19. The pillar links to the SLU-PP-332 product page in 5 places using varied anchor text (mix of partial-match, branded and natural anchors).